All In Biotech

Drug Trial Radar · NCT04089566

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Mar 26, 2020

Primary completion

Feb 21, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 7 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C). The secondary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A, B and C); to examine the effect of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA, to examine the effect of nusinersen administered intrathecally at higher doses compared to the currently approved dose in participants with SMA (Part B).

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • NusinersenDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control GroupTime frame: Baseline, Day 183
  2. Parts A and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)Time frame: Part A: From the first dose of the study drug up to Day 389, Part C: From the first dose of the study drug up to Day 361
  3. Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)Time frame: Parts A and C: Baseline up to Day 302
  4. Parts A and C: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)Time frame: Parts A and C: Baseline up to Day 302
  5. Parts A and C: Number of Participants With Shifts From Baseline in UrinalysisTime frame: Parts A and C: Baseline up to Day 302
  6. Parts A and C: Number of Participants With Shifts From Baseline in Cerebrospinal Fluid (CSF) ParametersTime frame: Part A: Baseline up to Day 269, Part C: Baseline up to Day 241
  7. Parts A and C: Number of Participants With Shifts From Baseline in Electrocardiograms (ECGs)Time frame: Parts A and C: Baseline up to Day 302
  8. Parts A and C: Number of Participants With Abnormalities in Vital Sign ParametersTime frame: Parts A and C: Baseline up to Day 302
  9. Parts A and C: Change From Baseline in Growth Parameters (Body Height)Time frame: Parts A and C: Baseline, Day 302
  10. Part C: Change From Baseline in Growth Parameters (Head Circumference)Time frame: Baseline, Day 302
  11. Part C: Change From Baseline in Growth Parameters (Chest Circumference)Time frame: Baseline, Day 302
  12. Part C: Change From Baseline in Growth Parameters (Arm Circumference)Time frame: Baseline, Day 302
  13. Parts A and C: Change From Baseline in Growth Parameters (Ulnar Length)Time frame: Parts A and C: Baseline, Day 302
  14. Parts A and C: Change From Baseline in Growth Parameters (Weight for Age Percentile)Time frame: Parts A and C: Baseline, Day 302
  15. Part C: Change From Baseline in Growth Parameters (Weight for Length Ratio)Time frame: Baseline, Day 302
  16. Part C: Change From Baseline in Growth Parameters (Head-to-Chest Circumference Ratio)Time frame: Baseline, Day 302
  17. Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (Activated Partial Thromboplastin Time (aPTT))Time frame: Parts A and C: Baseline up to Day 269
  18. Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (Prothrombin Time (PT))Time frame: Parts A and C: Baseline up to Day 269
  19. Parts A and C: Number of Participants With Shifts From Baseline in Coagulation Parameters (International Normalized Ratio (INR))Time frame: Parts A and C: Baseline up to Day 269
  20. Parts A and C: Change From Baseline in Urine Total ProteinTime frame: Parts A and C: Baseline, Day 302
  21. Parts A and C: Number of Participants With Neurological Examination Abnormalities Reported as AEsTime frame: Parts A and C: Baseline up to Day 302
  22. Parts A and C: Percentage of Participants With a Postbaseline Platelet Count Below the Lower Limit of Normal on at Least 2 Consecutive MeasurementsTime frame: Parts A and C: Baseline up to Day 302
  23. Parts A and C: Percentage of Participants With a Postbaseline Corrected QT Interval Using Fridericia's Formula (QTcF) of > 500 Millisecond (Msec) and an Increase From Baseline to Any Postbaseline Timepoint in QTcF of > 60 MsecTime frame: Parts A and C: Baseline up to Day 302

Locations

45 sites in 18 countries. Site status is shown where the registry gives one.

  • Stanford Hospital and Clinics

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • HC-UFMG - Hospital das Clinicas da Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clínicas da Faculdade de Medicina da USP

    São Paulo, São Paulo, Brazil

  • London Health Sciences Centre (LHSC) - Children's Hospital

    London, Ontario, Canada

  • Hospital Luis Calvo Mackenna

    Santiago, Chile

  • Clinica Las Condes

    Santiago, Chile

  • Clinica MEDS La Dehesa

    Santiago, Chile

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • The Children's Hospital of Zhejiang University school of Med_Hangzhou

    Hangzhou, Binjiang, China

  • Guangzhou Woman and Children's Medical Center

    Guangzhou, Guangzhou, China

  • Xiangya Hospital, Central South University

    Changsha, Hu'nan, China

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Fundacion Hospitalaria San Vicente de Paul

    Medellín, Colombia

  • Tallinn Children's Hospital

    Tallinn, Estonia

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH

    Giessen, Hesse, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • Magyarorszagi Reformatus Egyhaz Bethesda Gyermekkorhaz

    Budapest, Hungary

  • Fondazione Serena Onlus - Centro Clinico Nemo

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Kurume University Hospital

    Kurume-shi, Fukuoka, Japan

  • Hyogo College of Medicine Hospital

    Nishinomiya-shi, Hyōgo, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo-To, Japan

  • Saint George University Hospital Medical Center

    Beirut, Lebanon

  • Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Jalisco, Mexico

  • Instituto Nacional de Pediatria

    Mexico City, Mexico City, Mexico

  • Hospital Infantil de Mexico Federico Gomez

    Mexico City, Mexico City, Mexico

  • Instytut Pomnik - Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Russian Children Neuromuscular Center of Veltischev

    Moskva, Russia

  • Regional Pediatric Clinical Hospital #1

    Yekaterinburg, Russia

  • King Fahad Specialist Hospital

    Dammam, Saudi Arabia

  • National Guard Health Affairs: King Abdulaziz Medical City

    Jeddah, Saudi Arabia

  • King Faisal Specialist Hospital & Research Center

    Riyadh, Saudi Arabia

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.